On Friday, Baird reaffirmed its Outperform rating on shares of ResMed (NYSE:RMD), with a steady price target of $280.00. The endorsement comes despite acknowledging some investor concerns about the company's earnings per share (EPS) and operating margin (OM) projections, as well as the anticipated re-entry of competitors into the market.
The firm addressed the feedback received from investors, primarily those with a long-only orientation, who have scrutinized the long-term assumptions in Baird's model, especially regarding the potential impact of competitors like PHG and the introduction of GLP-1 treatments.
Some investors have also expressed skepticism about the Outperform rating due to what they perceive as aggressive EPS/OM assumptions and the expected financial performance in the fiscal year 2025, along with the perceived limited downside risks factored into the model.
Despite these concerns, Baird remains optimistic about ResMed's future. The company's Analyst Day is scheduled for Monday, and while it is not anticipated that management will set explicit revenue or EPS growth targets, Baird suggests that any dips in share price could present buying opportunities for investors.
The analyst's comments indicate that while the recent performance of ResMed's stock has been strong, some caution among investors is understandable given the variables at play. Baird's stance suggests a belief in the resilience and potential of ResMed, even as it acknowledges the fair points raised by investors regarding competition and financial projections.
In other recent news, ResMed has been the focus of multiple analyst reviews. Baird initiated coverage on ResMed shares with an Outperform rating, citing potential benefits from a growing market for continuous positive airway pressure (CPAP) devices.
On the other hand, Wolfe Research downgraded ResMed from Peer Perform to Underperform due to concerns about potential market disruption from Eli Lilly (NYSE:LLY)'s expected new medication for obstructive sleep apnea. Needham also downgraded its rating from Buy to Hold, citing anticipated challenges in the competitive landscape and slowing growth. However, William Blair maintained an Outperform rating on ResMed, anticipating a significant increase in sleep apnea and CPAP patients by 2025.
ResMed's recent financial performance has been robust, with a 9% increase in group revenue for the fourth quarter of fiscal year 2024, reaching $1.22 billion. This growth was primarily driven by strong mask sales in the United States. Additionally, ResMed reported a 10% increase in its quarterly dividend to shareholders, reduced its debt by $300 million, and repurchased 232,000 shares for $50 million. The company also indicated plans to invest in research and development, pursue acquisitions, and continue its share buyback program.
These developments reflect the recent performance and market dynamics of ResMed, with CLSA and RBC Capital revising their price targets for ResMed to AUD35.00 and AUD206.00 respectively.
InvestingPro Insights
As Baird reasserts its confidence in ResMed (NYSE:RMD), real-time data from InvestingPro underscores the company's financial robustness and market performance. ResMed's market capitalization stands at a solid $35.64 billion, reflecting its substantial presence in the medical equipment industry. The company's P/E ratio, currently at 34.99, indicates a premium valuation, which aligns with Baird's optimistic outlook despite the high earnings multiple noted in InvestingPro Tips. Additionally, the company's revenue growth over the last twelve months is an impressive 10.95%, showcasing its ability to expand in a competitive market.
InvestingPro Tips further reveal that ResMed has consistently rewarded its shareholders, raising its dividend for 12 consecutive years, and maintaining dividend payments for 13 consecutive years. This consistency in returning value to investors could be a reassuring signal for those concerned about the company's future amidst competitive pressures. Moreover, the company has demonstrated a strong return over the last year, with a price total return of 64.87%, reflecting investor confidence and market performance that may justify Baird's Outperform rating.
For investors looking for more detailed analysis, InvestingPro offers additional tips on ResMed's financial health and market potential. These insights, including the company's ability to cover interest payments with cash flows and its moderate level of debt, provide a deeper understanding of the factors that may influence its stock performance. With these metrics in mind, and considering the 15 additional tips listed on InvestingPro, investors can evaluate the opportunities that ResMed presents as it approaches its Analyst Day and beyond.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.